Cairnbridge
About the project

About

Cairnbridge is an independent resource on ibogaine, Parkinson’s research, safety considerations, and Switzerland’s regulatory landscape. We aim to help patients, families, researchers and policy-minded readers navigate evidence, uncertainty and risk with clear, plainspoken explanations.

Close-up detail view related to ibogaine, Parkinson's research and Swiss context, photographic study

Our editorial approach

We assemble material with an emphasis on primary sources and cautious synthesis. When describing research or regulatory frameworks we draw on registries, peer-reviewed literature, and official agency communications; where appropriate we point readers to original regulatory notices and trial registries so they can verify details themselves. For example, clinical registries and published trials are primary touchpoints for our summaries and bibliographies.

To maintain transparency we publish clear notes about sourcing and methods within reports and link inline to the original sources when available; this makes it straightforward to follow the trail from summary to primary evidence without loss of context.

What we cover

Content is organized thematically: concise briefs that summarise the current state of knowledge, dedicated safety and interaction guides, and region-specific regulatory context. Editorial units are intentionally compact so readers can scan findings quickly, then drill into referenced studies or official guidance as needed.

Who this is for

Our audience includes patients and families looking for balanced context, researchers seeking a compact synthesis of literature and regulatory signals, and policy-minded readers who want clarity about how evidence and law interact. If you first came from an article link, you can always return to the site overview by following the link back to our root page using this concise site index to navigate the broader collection of content.

Sourcing and vetting

We prioritise primary sources: peer-reviewed articles, clinical trial registries, official regulatory documents, and authoritative syntheses. When summarising research we include study design, sample size and limitations so readers can see how robust the evidence is at a glance.

For claims about regulation or public-health guidance we consult official agency pages and legal notices; those references are sometimes to national regulators or international registries to ensure accuracy. As an example of the kind of authority we consult, regulatory frameworks are typically confirmed by national agency pages such as the U.S. Food and Drug Administration or comparable national bodies when relevant (U.S. FDA).

We also use well-established reference overviews to clarify methodological standards in evidence assessment; for methodological grounding we often refer to established resources such as the Cochrane Library and academic guidance on evidence synthesis (Evidence-based medicine overview on Wikipedia).

Editorial principles

  • Independence — we avoid conflicts of interest and disclose funding or material relationships.
  • Evidence over hype — we prioritise rigorous studies and clearly label preliminary findings.
  • Patient safety — safety concerns and adverse-event data are highlighted prominently.
  • Plain language — technical topics are translated into accessible summaries without removing nuance.
  • Regulatory clarity — where law or rules matter, we cite official notices and region-specific documents.

How to follow up

If you want a concise primer of how the site treats a topic, the Services page describes our practical offerings and tools for readers seeking deeper orientation; if you are returning from a topic page you can jump back to the overview at the root of the site to explore related report pages or regulatory summaries by following the site index link provided earlier.

For examples of reporting standards and trial registry searches we consult public registries and peer-review practices; readers may cross-check trial information with registries such as ClinicalTrials.gov for trial listings and status.

Independent by design

Cairnbridge is an independent information resource; we are not a clinic, medical provider, or licensed treatment centre. Our content is intended for informational purposes and is not medical or legal advice. Readers making health decisions should consult qualified health professionals and verify regulatory status in their jurisdiction. For region-specific regulatory context, our briefs link to official notices where available and note jurisdictional differences. For practical details on how ibogaine is administered in some settings, we provide explanatory material and a link that users have found useful when exploring administration methods and procedural contexts: see the overview on how is ibogaine administered for contextual background (procedural overview and administration contexts).